{
    "clinical_study": {
        "@rank": "43403", 
        "arm_group": {
            "arm_group_label": "afatinib, ribavirin, and weekly carboplatin/paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used."
        }, 
        "brief_summary": {
            "textblock": "This study seeks to develop a new induction chemotherapy regimen which is a combination of\n      two pill drugs taken by mouth and two drugs given by vein. This is a phase I study, which\n      means that the primary goal is to establish the recommended dose of an investigational drug\n      when added to chemotherapy. The researchers wish to evaluate the effects, good and bad, of\n      the investigational drug."
        }, 
        "brief_title": "Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Head and Neck Cancer", 
            "Squamous Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Department of Pathology at MSKCC confirmation of diagnosis of oropharynx squamous\n             cell cancer, stage IVA/IVB, that is HPV associated.\n\n        Evidence of HPV can be p16 immunohistochemistry and/or HPV in situ hybridization positive\n        test result on tumor tissue, either at MSKCC or other CLIA-approved lab.\n\n          -  Age \u2265 18 years of age\n\n          -  Karnofsky Performance Status \u2265 80\n\n          -  Adequate organ function, as follows:\n\n        Adequate bone marrow reserve: absolute neutrophil count (ANC) \u2265 1.5 X 109/L, platelets \u2265\n        160 X 109/L, hemoglobin \u2265 12 g/dL Hepatic: total bilirubin within normal limits (\u2264 1.0\n        mg/dL); alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase\n        (ALT) \u2264 1.5 X ULN (upper limit of normal) Renal: Serum creatinine \u2264 1.3 mg/dL. Patients\n        with serum creatinine > 1.3 mg/dL may be eligible if creatinine clearance (CrCl) \u2265 55\n        mL/min based on the standard Cockroft and Gault formula.\n\n          -  Patients of childbearing potential must have a negative serum pregnancy test within\n             14 days of treatment. Patients must agree to use a reliable method of birth control\n             during and for 6 months following the last dose of study drug.\n\n          -  Ability to swallow oral medication.\n\n          -  Expansion Cohort only: At least one unstained slide from pre-treatment diagnostic\n             biopsy or fine needle aspirate must be available for correlative immunohistochemistry\n             study.\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy or radiation for tonsillar or base of tongue squamous cell cancer\n\n          -  History of hemolytic anemia or thalassemia\n\n          -  Active infection or serious underlying medical condition that would impair the\n             patient's ability to receive protocol treatment.\n\n          -  Current therapeutic anticoagulation with Coumadin (warfarin)\n\n          -  Current or prior treatment with ribavirin\n\n          -  Known active Hepatitis B or C\n\n          -  Any prior documented history of transient ischemic attack (TIA) or cerebrovascular\n             accident (CVA)\n\n          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure\n\n          -  Clinically significant peripheral vascular disease\n\n          -  Inability to discontinue any of the following potent P-gp inhibitors (cyclosporine,\n             erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with\n             quinidine, ritonavir, valspodar, verapamil) or inducers (St John's wort, rifampicin).\n\n          -  Known pre-existing interstitial lung disease.\n\n          -  Presence of poorly controlled gastrointestinal disorders that could affect the\n             absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis,\n             malabsorption, or CTC grade \u22652 diarrhea of any etiology) based on treating physician\n             assessment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721525", 
            "org_study_id": "12-150"
        }, 
        "intervention": {
            "arm_group_label": "afatinib, ribavirin, and weekly carboplatin/paclitaxel", 
            "description": "Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects \u226475 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.", 
            "intervention_name": "Afatinib, Ribavirin, and  weekly carboplatin/paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": [
                "During the Expansion Cohort (Part 2), there is a two week run in of afatinib +", 
                "ribavirin. The Expansion Cohort begins with a Run-In period of approximately", 
                "14 days, in which patients receive only afatinib + ribavirin. On Day -14", 
                "(Start of the of the Run-In), patients begin afatinib once daily (at 40 mg/daily the dose", 
                "established in Part 1) and ribavirin twice daily according to standard", 
                "weight-based dosing. Both afatinib and ribavirin are self-administered each", 
                "day during the Run-In period."
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "BIBW2992 (AFATINIB)", 
            "CARBOPLATIN", 
            "RIBAVIRIN-ICN (VIRAZOLE)", 
            "TAXOL (PACLITAXEL)", 
            "OROPHARYNX", 
            "HPV associated", 
            "12-150"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Matthew Fury, MD, PhD", 
                    "phone": "646-888-4233"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07939"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Basking Ridge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Matthew Fury, MD, PhD", 
                    "phone": "646-888-4233"
                }, 
                "contact_backup": {
                    "last_name": "David Pfiser, MD", 
                    "phone": "646-888-4232"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Matthew Fury, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)", 
        "overall_contact": {
            "last_name": "Matthew Fury, MD PhD", 
            "phone": "646-888-4233"
        }, 
        "overall_contact_backup": {
            "last_name": "David Pfister, MD", 
            "phone": "646-888-4232"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Matthew Fury, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "of daily oral afatinib administered with standard daily weight based ribavirin and intravenous carboplatin and paclitaxel, Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.", 
                "measure": "maximum tolerated dose (For Dose Escalation Portion of the study)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To determine if a two week run-in with afatinib and ribavirin results in increased expression of PTPN13, as determined by IHC in pre and post treatment biopsies.", 
                "measure": "expression of PTPN13 (For Expansion Cohort only)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721525"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events (AEs) will be assessed according to NCI common toxicity criteria (CTC) version 4.0. Dose Limiting Toxicity (DLT) include all toxicities of grade 3 or higher felt to be possibly, probably, or definitely related to study drug.", 
                "measure": "safety and tolerability (toxicity)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Response and progression will be evaluated in this study using modified international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) (51). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.", 
                "measure": "objective response rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "PK measurements will be collected from patients in the dose excalation cohort during the first cycle of therapy. The area under the curve (AUC0\u2192\u221e), half-life (t\u00bd), and maximum concentration (Cmax) for afatinib will be determined by noncompartmental analysis.", 
                "measure": "pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Comprehensive Cancer Network", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Boehringer Ingelheim", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}